Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent (NYSE:A) launched the 9500 Triple Quadrupole ICP-MS, a next-generation inductively coupled plasma mass spectrometry system aimed at labs moving from single to triple quadrupole technology.
The 9500 offers over 33% typical reduction in acquisition time, advanced interference removal via Air Cell and Advanced Helium Mode using the Dual-Cell System, and integration with OpenLab ICP-MS software. It targets environmental, food, pharma, chemical, materials, and contract testing labs, aiming to boost productivity, reduce reruns, and lessen reliance on oxygen cylinders.
Agilent (NYSE:A) launched the 1290 Infinity III Fluorescence Detector, a fluorescence detector optimized for modern UHPLC workflows. It combines ultra-trace sensitivity, UHPLC-ready chromatographic performance, and ease of use for standalone operation or in-line LC/MS setups.
The detector preserves narrow UHPLC peak integrity while delivering rich spectral information, supporting trace-level analysis in biopharma, food safety, and environmental applications.
Agilent (NYSE:A) declared a quarterly cash dividend of $0.255 per share of common stock. The dividend is payable on July 22, 2026 to shareholders of record as of June 30, 2026. Agilent reported $6.95 billion in fiscal 2025 revenue and employs about 18,000 people worldwide.
Agilent (NYSE:A) announced a TSA contract to deploy its new Bulk Alarm Resolution Technology (BRT) at U.S. airport security checkpoints in FIFA World Cup 2026 host cities.
The BRT uses Surface Offset Raman Spectroscopy and algorithms to quickly confirm liquids, gels, creams, solids, and powders through various containers, aiming to enhance detection, efficiency, and traveler experience.
Agilent (NYSE:A) will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, at 9:20 a.m. EDT in New York City.
A live audio webcast and replay will be available on Agilent’s investor relations website. Agilent reported $6.95 billion fiscal 2025 revenue and employs about 18,000 people.
Agilent (NYSE: A) named Michael Buckner as chief legal officer, effective May 4, 2026. Buckner brings nearly three decades of senior global legal experience across mergers and acquisitions, antitrust, intellectual property and regulatory matters.
He joins from Danaher, where he led M&A legal strategy including the Abcam acquisition and Veralto spin-off. Agilent reported fiscal 2025 revenue of $6.95 billion and about 18,000 employees.
Agilent (NYSE: A) will report second-quarter fiscal 2026 results after the market close on May 27, 2026 and will host a listen-only conference call webcast at 1:30 p.m. PDT the same day. A recording will be available on the investor website for 90 days.
Agilent reported $6.95 billion revenue for fiscal 2025 and employs about 18,000 people worldwide. Webcast access is via the Events section of Agilent's Investor Relations site.
Agilent (NYSE: A) will showcase cancer research solutions at the AACR Annual Meeting in San Diego, April 17–22, 2026. Highlights include the new BioTek Cytation 9, an AI-enabled preview for xCELLigence RTCA eSight, SureSelect compatibility with Oxford Nanopore long-read sequencing, and user events.
Agilent will exhibit at booth 4527 and continue support for early-career researchers via AACR Foundation initiatives.
Agilent (NYSE: A) on April 1, 2026 announced the BioTek Cytation 9, a new cell imaging multimode reader combining multimode microplate detection with high-content imaging in one platform.
Cytation 9 adds inverted fluorescence and upright imaging optics, a multimode reader module, and claims twice the imaging speed, targeting higher-throughput cell‑based and biochemical workflows for research and drug discovery.
TORM plc (NASDAQ: TRMD A) increased share capital by 43,697 A-shares following exercise of Restricted Share Units on March 31, 2026. 10,634 shares were subscribed at DKK 131.80 and 33,063 at DKK 148.70. Post-issue share capital is USD 1,021,233.39 across 102,123,339 A-shares.
New shares are ordinary, carry dividend and voting rights from issuance, and are expected to list on Nasdaq Copenhagen as soon as possible.